Table of Contents Author Guidelines Submit a Manuscript
Scientifica
Volume 2012, Article ID 238278, 28 pages
http://dx.doi.org/10.6064/2012/238278
Review Article

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance

Lady Davis Institute, McGill University AIDS Centre, Jewish General Hospital, Montreal, QC, Canada H3T 1E2

Received 13 September 2012; Accepted 1 November 2012

Academic Editors: M. Clementi, C. Marchand, H. J. Netter, and B. Peterson

Copyright © 2012 Mark A. Wainberg. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Panel, Antiretroviral, Guidelines, for, Adults, and Adolesscent, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2011, http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf.
  2. P. G. Yeni, S. M. Hammer, C. C. J. Carpenter et al., “Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel,” JAMA, vol. 288, no. 2, pp. 222–235, 2002. View at Google Scholar · View at Scopus
  3. J. E. Gallant, P. Z. Gerondelis, M. A. Wainberg et al., “Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance,” Antiviral Therapy, vol. 8, no. 6, pp. 489–506, 2003. View at Google Scholar · View at Scopus
  4. F. J. Palella Jr., K. M. Delaney, A. C. Moorman et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection,” The New England Journal of Medicine, vol. 338, no. 13, pp. 853–860, 1998. View at Publisher · View at Google Scholar
  5. J. D. Roberts, K. Bebenek, and T. A. Kunkel, “The accuracy of reverse transcriptase from HIV-1,” Science, vol. 242, no. 4882, pp. 1171–1173, 1988. View at Google Scholar · View at Scopus
  6. J. M. Coffin, “HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy,” Science, vol. 267, no. 5197, pp. 483–489, 1995. View at Google Scholar · View at Scopus
  7. D. D. Ho, A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz, “Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection,” Nature, vol. 373, no. 6510, pp. 123–126, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. T. B. Kepler and A. S. Perelson, “Drug concentration heterogeneity facilitates the evolution of drug resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 20, pp. 11514–11519, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. O. J. D'Cruz and F. M. Uckun, “Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 21, no. 4, pp. 329–350, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Ren, R. Esnouf, E. Garman et al., “High resolution structures of HIV-1 RT from four RT-inhibitor complexes,” Nature Structural Biology, vol. 2, no. 4, pp. 293–302, 1995. View at Google Scholar
  11. F. D. Bushman, T. Fujiwara, and R. Craigie, “Retroviral DNA integration directed by HIV integration protein in vitro,” Science, vol. 249, no. 4976, pp. 1555–1558, 1990. View at Google Scholar · View at Scopus
  12. R. Krebs, U. Immendörfer, S. H. Thrall, B. M. Wöhrl, and R. S. Goody, “Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC,” Biochemistry, vol. 36, no. 33, pp. 10292–10300, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. U. M. Parikh, S. Zelina, N. Sluis-Cremer, and J. W. Mellors, “Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase,” AIDS, vol. 21, no. 11, pp. 1405–1414, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. A.-G. Marcelin, Antiretroviral Resistance in Clinical Practice, Mediscript, London, UK, 2006.
  15. V. Miller, M. Ait-Khaled, C. Stone et al., “HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy,” AIDS, vol. 14, no. 2, pp. 163–171, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. U. M. Parikh, L. Bacheler, D. Koontz, and J. W. Mellors, “The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations,” Journal of Virology, vol. 80, no. 10, pp. 4971–4977, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. B. G. Brenner, M. Oliveira, F. Doualla-Bell et al., “HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture,” AIDS, vol. 20, no. 9, pp. F9–F13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Ribera Pascuet and A. Curran, “Current role of tenofovir DF in clinical practice,” Enfermedades Infecciosas y Microbiologia Clinica, vol. 26, supplement 8, pp. 45–54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Brenner, D. Turner, M. Oliveira et al., “A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors,” AIDS, vol. 17, no. 1, pp. F1–F5, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. D. W. Ludovici, B. L. De Corte, M. J. Kukla et al., “Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues,” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 17, pp. 2235–2239, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Antinori, E. Girardi, A. De Luca et al., “Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure,” AIDS Research and Human Retroviruses, vol. 18, no. 12, pp. 835–838, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. D. W. Ludovici, M. J. Kukla, P. G. Grous et al., “Evolution of anti-HIV drug candidates. Part 1: from α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU),” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 17, pp. 2225–2228, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Bennett, L. McCormick, and R. kLien, “US surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera,” in Proceedings of the 12th Conference on Retroviruses and Opportunitic Infections, Boston, Mass, USA, 2005.
  24. R. A. Domaoal and L. M. Demeter, “Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors,” International Journal of Biochemistry and Cell Biology, vol. 36, no. 9, pp. 1735–1751, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. L. A. Kohlstaedt, J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz, “Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexes with an inhibitor,” Science, vol. 256, no. 5065, pp. 1783–1790, 1992. View at Google Scholar · View at Scopus
  26. J. Z. Y. Fabrycki, J. Wearne, Y. Sun et al., “In vitro introduction of hiv variants with reduced susceptibility to elvucitabine (AHC-126, 443, B-L-FD4C),” in Proceedings of the 12th International HIV Drug Resistance Workshop, Mexico, 2003.
  27. P. Colucci, J. C. Pottage, H. Robison et al., “Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 662–669, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. Z. Gu, Z. N. B, C. Ren et al., “BCH-10618, a new heterosubstituted nucleoside analogue against HIV-1 infection,” Antiviral Therapy, vol. 6, supplement 1, article 8, 2001. View at Google Scholar
  29. M. Oliveira, D. Moisi, B. Spira, S. Cox, B. G. Brenner, and M. A. Wainberg, “Apricitabine does not select additional drug resistance mutations in tissue culture in human immunodeficiency virus type 1 variants containing K65R, M184V, or M184V plus thymidine analogue mutations,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 4, pp. 1683–1685, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. P. Cahn and M. A. Wainberg, “Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 2, pp. 213–217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. E. I. Kodama, S. Kohgo, K. Kitano et al., “4′-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 5, pp. 1539–1546, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Kawamoto, E. Kodama, S. G. Sarafianos et al., “2′-Deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 11, pp. 2410–2420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. E. R. Lanier, R. G. Ptak, B. M. Lampert et al., “Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 7, pp. 2901–2909, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Michailidis, B. Marchand, E. N. Kodama et al., “Mechanism of inhibition of HIV-1 reverse transcriptase by 4′-ethynyl-2-fluoro-2′-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor,” The Journal of Biological Chemistry, vol. 284, no. 51, pp. 35681–35691, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. C. D. Sohl, K. Singh, R. Kasiviswanathan et al., “The mechanism of interaction of huma mitochondrial DNA polymerase gamma with the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine indicates a low potential for host toxicity,” Antimicrob Agents Chemother, vol. 56, no. 3, pp. 1630–1634, 2011. View at Google Scholar
  36. T. Cihlar, A. S. Ray, C. G. Boojamra et al., “Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 2, pp. 655–665, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. A. S. Ray, J. E. Vela, C. G. Boojamra et al., “Intracellular metabolism of the nucleotide prodrug GS-9131, a potent anti-human immunodeficiency virus agent,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 2, pp. 648–654, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. W. A. Lee, G. X. He, E. Eisenberg et al., “Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 5, pp. 1898–1906, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. E. D. Peter Ruane, D. Berger, M. Markowitz et al., “GS-7340 25 mg and 40 mg demonstrate superior efficacy to tenofovir 300 mg in a 10-day monotherapy study of HIV-1+ patients,” in Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections, 2012.
  40. Gilead Sciences, I. Viread (tenofovir disoproxyl fumurate) tablets prescribing information, 2012, http://www.gilead.com/pdf/viread_pi.pdf.
  41. A. S. Ray, T. Cihlar, K. L. Robinson et al., “Mechanism of active renal tubular efflux of tenofovir,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 10, pp. 3297–3304, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. G. R. Painter, M. R. Almond, L. C. Trost et al., “Evaluation of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 10, pp. 3505–3509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. J. P. Mewshaw, F. T. Myrick, D. A. C. S. Wakefield et al., “Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails,” Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 1, pp. 11–20, 2002. View at Google Scholar · View at Scopus
  44. H. Z. Bazmi, J. L. Hammond, S. C. H. Cavalcanti, C. K. Chu, R. F. Schinazi, and J. W. Mellors, “In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-β-D-dioxolane- guanosine and suppress resistance to 3′-azido-3′-deoxythymidine,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 7, pp. 1783–1788, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. R. L. Murphy, N. M. Kivel, C. Zala et al., “Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebocontrolled study in HIV-1-infected individuals,” Antiviral Therapy, vol. 15, no. 2, pp. 185–192, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Weber, J. J. W, A. C. Vazquez et al., “Drug susceptibility profile of OBP-601, a novel NRTI, using a comprehensive panel of NRTI and/or NNRTI resistant viruses,” in Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, Mass, USA, 2008, Abstract no. 726.
  47. K. Andries, H. Azijn, T. Thielemans et al., “TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 12, pp. 4680–4686, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. J. Vingerhoets, H. Azijn, E. Fransen et al., “TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments,” Journal of Virology, vol. 79, no. 20, pp. 12773–12782, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. V. Briz, C. Garrido, E. Poveda et al., “Raltegravir and etravirine are active against HIV Type 1 group O,” AIDS Research and Human Retroviruses, vol. 25, no. 2, pp. 225–227, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. J. V. Madruga, P. Cahn, B. Grinsztejn et al., “Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 370, no. 9581, pp. 29–38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. J. P. Nadler, D. S. Berger, G. Blick et al., “Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis,” AIDS, vol. 21, no. 6, pp. F1–F10, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Vingerhoets, L. Tambuyzer, H. Azijn et al., “Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies,” AIDS, vol. 24, no. 4, pp. 503–514, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. E. L. Asahchop, M. Oliveira, M. A. Wainberg, B. G. Brenner, T. D. Toni, and C. L. Tremblay, “Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 600–607, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. L. Tambuyzer, S. Nijs, B. Daems, G. Picchio, and J. Vingerhoets, “Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine,” JAIDS Journal of Acquired Immune Deficiency Syndromes, vol. 58, no. 1, pp. 18–22, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Das, A. D. Clark, P. J. Lewi et al., “Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants,” Journal of Medicinal Chemistry, vol. 47, no. 10, pp. 2550–2560, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Katlama, B. Clotet, A. Mills et al., “Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials,” Antiviral Therapy, vol. 15, no. 7, pp. 1045–1052, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. A. G. Marcelin, P. Flandre, D. Descamps et al., “Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced hiv-1-infected patients,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 1, supplement 2, pp. 72–77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. L. Tambuyzer, J. Vingerhoets, H. Azijn et al., “Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies,” AIDS Research and Human Retroviruses, vol. 26, no. 11, pp. 1197–1205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Trottier, G. Di Perri, J. Madruga et al., “Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and-2,” HIV Clinical Trials, vol. 11, no. 4, pp. 175–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Ruxrungtham, R. J. Pedro, G. H. Latiff et al., “Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227,” HIV Medicine, vol. 9, no. 10, pp. 883–896, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J. M. Llibre, J. R. Santos, T. Puig et al., “Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz,” Journal of Antimicrobial Chemotherapy, vol. 62, no. 5, pp. 909–913, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. E. Poveda, C. Garrido, C. De Mendoza et al., “Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 6, pp. 1409–1410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. U. Neogi, A. Shet, R. Shamsundar, and M. L. Ekstrand, “Selection of nonnucleoside reverse transcriptase inhibitor-associated mutations in HIV-1 subtype C: evidence of etravirine cross-resistance,” AIDS, vol. 25, no. 8, pp. 1123–1125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Poveda, L. Anta, J. L. Blanco et al., “Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database,” AIDS, vol. 24, no. 3, pp. 469–471, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Lapadula, A. Calabresi, F. Castelnuovo et al., “Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors,” Antiviral Therapy, vol. 13, no. 4, pp. 601–605, 2008. View at Google Scholar · View at Scopus
  66. S. Kiertiburanakul, S. Wiboonchutikul, C. Sukasem, W. Chantratita, and S. Sungkanuparph, “Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting,” Journal of Clinical Virology, vol. 47, no. 4, pp. 330–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. A. F. D. Kekitiinwa, E. Coakley, Y. Lie, and F. Granziano, “Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI-inclusive regimen as first-line ART,” in Proceedings of the 6th Conference on Retroviruses and Opportunistic and Infections (CROI '10), San Francisco, Calif, USA, 2010, Abstract no. 891.
  68. W. Manosuthi, D. M. Butler, W. Chantratita, C. Sukasem, D. D. Richman, and D. M. Smith, “Patients infected with HIV type 1 subtype CRF01-AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine,” AIDS Research and Human Retroviruses, vol. 26, no. 6, pp. 609–611, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. A. I. Maïga, D. Descamps, L. Morand-Joubert et al., “Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 2, pp. 728–733, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. V. Varghese, R. Shahriar, S. Y. Rhee et al., “Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors,” Journal of Acquired Immune Deficiency Syndromes, vol. 52, no. 3, pp. 309–315, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Paredes, C. M. Lalama, H. J. Ribaudo et al., “Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure,” Journal of Infectious Diseases, vol. 201, no. 5, pp. 662–671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Gupta, S. Fransen, E. E. Paxinos, E. Stawiski, W. Huang, and C. J. Petropoulos, “Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 5, pp. 1973–1980, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Gupta, J. Vingerhoets, S. Fransen et al., “Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 6, pp. 2872–2879, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. A. L. McCormick, C. M. Parry, A. Crombe et al., “Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 4, pp. 1806–1809, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Haddad, E. S. J. Benhamida, and E. Coakley, “Improved genotypic algorith for predicting etravirine susceptibility: comprehensive list of mutations identified through correlation with matched phenotype,” in Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections (CROI '10), San Francisco, Calif, USA, 2010, Abstract no. 574.
  76. H. Azijn, I. Tirry, J. Vingerhoets et al., “TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 2, pp. 718–727, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. K. Das, J. D. Bauman, A. D. Clark et al., “High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 5, pp. 1466–1471, 2008. View at Publisher · View at Google Scholar · View at Scopus
  78. J. M. Molina, P. Cahn, B. Grinsztejn et al., “Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial,” The Lancet, vol. 378, no. 9787, pp. 238–246, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. C. J. Cohen, J. Andrade-Villanueva, B. Clotet et al., “Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial,” The Lancet, vol. 378, no. 9787, pp. 229–237, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Rimsky, J. Vingerhoets, V. Van Eygen et al., “Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis,” JAIDS, vol. 59, no. 1, pp. 39–46, 2012. View at Google Scholar
  81. V. A. Johnson, V. Calvez, H. F. Günthard et al., “Update of the drug resistance mutations in HIV-1,” Topics in Antiviral Medicine, vol. 19, no. 4, pp. 156–164, 2011. View at Google Scholar
  82. D. W. Ludovici, R. W. Kavash, M. J. Kukla et al., “Evolution of anti-HIV drug candidates. Part 2: diaryltriazine (DATA) analogues,” Bioorganic and Medicinal Chemistry Letters, vol. 11, no. 17, pp. 2229–2234, 2001. View at Google Scholar
  83. P. Fletcher, S. Harman, H. Azijn et al., “Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 487–495, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. S. M. Schader, S. P. Colby-Germinario, J. R. Schachter, H. Xu, and M. A. Wainberg, “Synergy against drug resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination,” AIDS, vol. 25, no. 13, pp. 1585–1594, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. A. M. Nel, P. Coplan, S. C. Smythe et al., “Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women,” AIDS Research and Human Retroviruses, vol. 26, no. 11, pp. 1181–1190, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. A. M. Nel, P. Coplan, J. H. Van De Wijgert et al., “Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women,” AIDS, vol. 23, no. 12, pp. 1531–1538, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. P. Selhorst, A. C. Vazquez, K. Terrazas-Aranda et al., “Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 4, pp. 1403–1413, 2011. View at Publisher · View at Google Scholar
  88. S. M. Schader, M. Oliveira, R.-I. Ibanescu et al., “The in vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine,” Antimicrob Agents Chemother, vol. 66, pp. 751–756, 2012. View at Google Scholar
  89. R. Corbau, J. Mori, C. Phillips et al., “Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 10, pp. 4451–4463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. P. W. C. Vernazza, A. Pozniak, C. Wang et al., “Efficacy and Safety of lersivirine (UK-453, 061) vs. efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, randomised, double-blind, phase IIb trial (study A5271015),” in Proceedings of the 6th IAS Conference on HIV Pathogenesis Treatment and Prevention, Rome, Italy, 2011.
  91. W. B. G. Xu, R. Straney, Z. Zhang et al., “Resistance to RDEA806 requires multiple mutations which have limited cross-resistance to other NNRTIs,” in Proceedings of the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC '08), Washington, DC, USA, 2008.
  92. G. Moyle, M. Boffito, A. Stoehr et al., “Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 8, pp. 3170–3178, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. J. M. Coffin, S. H. Hughes, and H. E. Varmus, Retroviruses, Cold Spring Harbor Laboratory Press, Harbor, NY, USA, 1997.
  94. S. P. Gupta and A. N. Nagappa, “Design and development of integrase inhibitors as anti-HIV agents,” Current Medicinal Chemistry, vol. 10, no. 18, pp. 1779–1794, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Sluis-Cremer and G. Tachedjian, “Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules,” European Journal of Biochemistry, vol. 269, no. 21, pp. 5103–5111, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Maurin, F. Bailly, and P. Cotelle, “Structure-activity relationships of HIV-1 integrase inhibitors—enzyme-ligand interactions,” Current Medicinal Chemistry, vol. 10, no. 18, pp. 1795–1810, 2003. View at Publisher · View at Google Scholar · View at Scopus
  97. S. B. Singh, H. Jayasuriya, G. M. Salituro et al., “The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I,” Journal of Natural Products, vol. 64, no. 7, pp. 874–882, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. N. Jing and X. Xu, “Rational drug design of DNA oligonucleotides as HIV inhibitors,” Current Drug Targets. Infectious Disorders, vol. 1, no. 2, pp. 79–90, 2001. View at Google Scholar · View at Scopus
  99. A. Brigo, G. I. Mustata, J. M. Briggs, and S. Moro, “Discovery of HIV-1 integrase inhibitors through a novel combination of ligand and structure-based drug design,” Medicinal Chemistry, vol. 1, no. 3, pp. 263–275, 2005. View at Publisher · View at Google Scholar · View at Scopus
  100. V. R. de Soultrait, C. Desjobert, and L. Tarrago-Litvak, “Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase,” Current Medicinal Chemistry, vol. 10, no. 18, pp. 1765–1778, 2003. View at Publisher · View at Google Scholar · View at Scopus
  101. D. J. Hazuda, P. Felock, M. Witmer et al., “Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells,” Science, vol. 287, no. 5453, pp. 646–650, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. R. Reinke, D. J. Lee, and W. E. Robinson, “Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo acid,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 10, pp. 3301–3303, 2002. View at Publisher · View at Google Scholar · View at Scopus
  103. D. Hazuda, M. Iwamoto, and L. Wenning, “Emerging pharmacology: inhibitors of human immunodeficiency virus integration,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 377–394, 2009. View at Publisher · View at Google Scholar · View at Scopus
  104. C. Marchand, X. Zhang, G. C. G. Pais et al., “Structural determinants for HIV-1 integrase inhibition by β-diketo acids,” The Journal of Biological Chemistry, vol. 277, no. 15, pp. 12596–12603, 2002. View at Publisher · View at Google Scholar · View at Scopus
  105. Y. Goldgur, R. Craigie, G. H. Cohen et al., “Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 23, pp. 13040–13043, 1999. View at Publisher · View at Google Scholar · View at Scopus
  106. Ltd., S.a.C., W09950245, 1999.
  107. M. J. C. Rosemond, L. St. John-Williams L., T. Yamaguchi, T. Fujishita, and J. S. Walsh, “Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases,” Chemico-Biological Interactions, vol. 147, no. 2, pp. 129–139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. FDA. FDA approval of Isentress (raltegravir), 2007.
  109. R. T. Steigbigel, D. A. Cooper, H. Teppler et al., “Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: week 96 results of the benchmrk 1 and 2 phase III trials,” Clinical Infectious Diseases, vol. 50, no. 4, pp. 605–612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. D. A. Donahue, R. D. Sloan, B. D. Kuhl, T. Bar-Magen, S. M. Schader, and M. A. Wainberg, “Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 3, pp. 1047–1054, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. B. Grinsztejn, B. Y. Nguyen, C. Katlama et al., “Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial,” The Lancet, vol. 369, no. 9569, pp. 1261–1269, 2007. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Iwamoto, “Rifampin (RIF) modestly reduces plasma levels of MK-0518,” in Proceedings of the 8th International Congress Drug Therapy in HIV Infection (HIV '06), L. A. Wenning, J. T. Kost, E. Mangin et al., Eds., Glasgow, Scotland, 2006.
  113. M. Markowitz, B. Y. Nguyen, E. Gotuzzo et al., “Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study,” Journal of Acquired Immune Deficiency Syndromes, vol. 46, no. 2, pp. 125–133, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. J. J. Eron, J. K. Rockstroh, J. Reynes et al., “Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial,” The Lancet Infectious Diseases, vol. 11, no. 12, pp. 907–915, 2011. View at Publisher · View at Google Scholar
  115. E. Vispo, P. Barreiro, I. Maida et al., “Simplification from protease inhibitors to once-or twice-daily raltegravir: the ODIS trial,” HIV Clinical Trials, vol. 11, no. 4, pp. 197–204, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. M. Lanzafame, A. Hill, E. Lattuada, A. Calcagno, and S. Bonora, “Raltegravir: is a 400 mg once-daily dose enough?” Journal of Antimicrobial Chemotherapy, vol. 65, no. 3, Article ID dkp488, pp. 595–597, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. I. Malet, O. Delelis, M. A. Valantin et al., “Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 4, pp. 1351–1358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  118. C. Garrido, C. de Mendoza, and V. Soriano, “Resistance to integrase inhibitors,” Enfermedades Infecciosas y Microbiología Clínica, vol. 26, supplement 12, pp. 40–46, 2008. View at Google Scholar
  119. T. Bar-Magen, D. A. Donahue, E. I. McDonough et al., “HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays,” AIDS, vol. 24, no. 14, pp. 2171–2179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  120. O. Delelis, I. Malet, L. Na et al., “The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation,” Nucleic Acids Research, vol. 37, no. 4, pp. 1193–1201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. V. A. Johnson, F. Brun-Vézinet, B. Clotet et al., “Update of the drug resistance mutations in HIV-1: December 2010,” Topics in HIV Medicine, vol. 18, no. 5, pp. 156–163, 2010. View at Google Scholar · View at Scopus
  122. Z. Hu and D. R. Kuritzkes, “Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness,” Journal of Acquired Immune Deficiency Syndromes, vol. 55, no. 2, pp. 148–155, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. F. Canducci, B. Barda, E. Ceresola et al., “Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption,” Clinical Microbiology and Infection, vol. 17, no. 6, pp. 928–934, 2011. View at Publisher · View at Google Scholar · View at Scopus
  124. D. A. Cooper, R. T. Steigbigel, J. M. Gatell et al., “Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection,” The New England Journal of Medicine, vol. 359, no. 4, pp. 355–365, 2008. View at Publisher · View at Google Scholar
  125. J. L. Blanco, V. Varghese, S. Y. Rhee, J. M. Gatell, and R. W. Shafer, “HIV-1 integrase inhibitor resistance and its clinical implications,” Journal of Infectious Diseases, vol. 203, no. 9, pp. 1204–1214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  126. J. J. Eron, B. Young, D. A. Cooper et al., “Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials,” The Lancet, vol. 375, no. 9712, pp. 396–407, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. O. M. Klibanov, “Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection,” Current Opinion in Investigational Drugs, vol. 10, no. 2, pp. 190–200, 2009. View at Google Scholar · View at Scopus
  128. M. Sato, T. Motomura, H. Aramaki et al., “Novel HIV-1 integrase inhibitors derived from quinolone antibiotics,” Journal of Medicinal Chemistry, vol. 49, no. 5, pp. 1506–1508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Matsuzaki, “JTK-303/GS 9137, a novel small-molecule inhibitor of HIV-1 integrase: anti-HIV activity profile and pharmacokinetics in animals,” in Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections (CROI '06), Denver, Colo, USA, 2006.
  130. Annonymous, “Single-tablet Quad regimen achieves high rate of virologic suppression,” AIDS Patient Care STDS, vol. 24, no. 3, article 197, 2010. View at Google Scholar
  131. S. Ramanathan, A. A. Mathias, P. German, and B. P. Kearney, “Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir,” Clinical Pharmacokinetics, vol. 50, no. 4, pp. 229–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. A. A. Mathias, S. West, J. Hui, and B. P. Kearney, “Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure,” Clinical Pharmacology and Therapeutics, vol. 85, no. 1, pp. 64–70, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. K. Isao, T. Ishikawa, M. Ishibashi, S. Irie, and A. Kakee, “Safety and pharmacokinetics of single oral dose of JTK-303/GS-9137, a novel HIV integrase inhibitor, in healthy volunteers,” in Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections (CROI '06), Denver, Colo, USA, 2006.
  134. R. Elion, J. Gathe, B. Rashbaum et al., “The single-tablet regimen elvitegravir/cobicstat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; “QUAD”) maintains a high rate of virologic supression, and cobicstat (COBI) is an effective pharmacoenhancer through 48 weeks,” in Proceedings of the 50th International Conference on Antimicrobial Agents and Chemotherapy, Boston, Mass, USA, 2010.
  135. A. R. Zolopa, D. S. Berger, H. Lampiris et al., “Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial,” Journal of Infectious Diseases, vol. 201, no. 6, pp. 814–822, 2010. View at Publisher · View at Google Scholar · View at Scopus
  136. O. Goethals, R. Clayton, M. Van Ginderen et al., “Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors,” Journal of Virology, vol. 82, no. 21, pp. 10366–10374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. B. Taiwo, L. Zheng, S. Gallien et al., “Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262),” AIDS, vol. 25, no. 17, pp. 2113–2122, 2011. View at Publisher · View at Google Scholar
  138. M. Métifiot, N. Vandegraaff, K. Maddali et al., “Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143,” AIDS, vol. 25, no. 9, pp. 1175–1178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  139. K. Shimura, E. Kodama, Y. Sakagami et al., “Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137),” Journal of Virology, vol. 82, no. 2, pp. 764–774, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. I. B. Dicker, B. Terry, Z. Lin et al., “Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors,” The Journal of Biological Chemistry, vol. 283, no. 35, pp. 23599–23609, 2008. View at Publisher · View at Google Scholar · View at Scopus
  141. D. J. McColl, S. Fransen, S. Gupta et al., “Rate of accumulation of thymidine analogue mutations (TAM) in patients left on virologically failing regimens containing zidovudine (ZDV) or stavudine (d4T),” in Proceedings of the 16th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, 2007.
  142. F. Canducci, M. Sampaolo, M. C. Marinozzi et al., “Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies,” AIDS, vol. 23, no. 4, pp. 455–460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. L. Q. Al-Mawsawi, R. I. Al-Safi, and N. Neamati, “Clinical progress of HIV-1 integrase inhibitors,” Expert Opinion on Emerging Drugs, vol. 13, no. 2, pp. 213–225, 2008. View at Publisher · View at Google Scholar · View at Scopus
  144. J. W. J. Vacca, T. Fisher, M. Embrey et al., “Discovery of MK-2048—subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitor, in,” in Proceedings of the 4th International AIDS Society's Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 2007.
  145. L. Van Wesenbeeck, E. Rondelez, M. Feyaerts et al., “Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 1, pp. 321–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  146. K. K. Pandey, S. Bera, A. C. Vora, and D. P. Grandgenett, “Physical trapping of HIV-1 synaptic complex by different structural classes of integrase strand transfer inhibitors,” Biochemistry, vol. 49, no. 38, pp. 8376–8387, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. O. Goethals, M. Van Ginderen, A. Vos et al., “Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor,” Antiviral Research, vol. 91, no. 2, pp. 167–176, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. T. Bar-Magen, R. D. Sloan, D. A. Donahue et al., “Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor,” Journal of Virology, vol. 84, no. 18, pp. 9210–9216, 2010. View at Publisher · View at Google Scholar · View at Scopus
  149. K. Alcorn, Raltegravir shows promise as a PREP drug, 2009, http://www.aidsmap.com/Raltegravir-shows-potential-for-use-as-PrEP-drug/page/1434320/.
  150. M. E. Seegulam and L. Ratner, “Integrase inhibitors effective against human T-cell leukemia virus type 1,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 5, pp. 2011–2017, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. J. Eron, J. Livrozet, P. Mortal et al., “Activity of integrase inhibitor S/GSK9572 in subjects with HIV exhibiting raltegravir resistance: week 24 results of VIKING Study,” in Proceedings of the 10th International Conference on Drug Therapy in HIV Infection, Glasgow, Scotland, 2010.
  152. M. K.-K. Tomokazu Yoshinaga, T. Seki, K. Ishida et al., “Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572,” in Proceedings of the International HIV & Hepatitis Virus Drug Resistance Workshop, Dubrovnik, Croatia, 2010.
  153. T. Bar-Magen, R. D. Sloan, V. H. Faltenbacher et al., “Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes,” Retrovirology, vol. 6, article 103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. R. D. Sloan and M. A. Wainberg, “The role of unintegrated DNA in HIV infection,” Retrovirology, vol. 8, article 52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  155. T. K. M. Seki, C. Wakasa-Morimoto, T. Yoshinaga et al., “No impact of HIV integrase polymorphisms at position 101 and 124 on in vitro resistance isolation with dolutegravir (DTG, S/GSK1349572), a potent next generation HIV integrase inhibitor,” in Proceedings of the 17th International Conference on Retroviruses and Opportunistic Infections (CROI '10), San Francisco, Calif, USA, 2010.
  156. M. J. B. Underwood, B. Johns, A. Sato et al., “S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy,” in Proceedings of the 5th International AIDS Society's Conference on HIV Pathogenesis, Cape Town, South Africa, 2009.
  157. M. Kobayashi, T. Yoshinaga, T. Seki et al., “In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 813–821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. S. Min, I. Song, J. Borland et al., “Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 1, pp. 254–258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. S. Min, L. Sloan, E. DeJesus et al., “Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults,” AIDS, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Min, L. Sloan, E. DeJesus et al., “Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults,” AIDS, vol. 25, no. 14, pp. 1737–1745, 2011. View at Publisher · View at Google Scholar · View at Scopus
  161. J. Rockstroh, F. F. F. Maggiolo, F. Pulido et al., “Once-daily S/GSK1349572 combination therapy in antiretroviral-naïve adults: rapid and potent 24-week antiviral responses in SPRING-1 (ING112276),” in Proceedings of the 10th International Conference on Drug Therapy in HIV Infection, Glasgow, Scotland, 2010.
  162. G. Jones, R. Ledford, F. Yu et al., “Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303),” in 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, Calif, USA, 2007.
  163. M. A. Wainberg et al., “Dolutegravir selects for R263K mutation in Subtype B and AG but not subtype C integrase enzymes,” in Proceedings of the 4th International Conference on Retroviral Integration, Siena, Italy, 2011.
  164. K. E. Hightower, R. Wang, F. DeAnda et al., “Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 10, pp. 4552–4559, 2011. View at Publisher · View at Google Scholar
  165. J. A. Grobler, P. M. McKenna, S. Ly et al., “Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors. in Therapy,” in Proceedings of the 10th International Conference on Clinical Pharmacology of HIV, Amsterdam, Netherlands, 2009.
  166. S. Hare, S. J. Smith, M. Métifiot et al., “Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572),” Molecular Pharmacology, vol. 80, no. 4, pp. 565–572, 2011. View at Publisher · View at Google Scholar
  167. C. Garrido, V. Soriano, A. M. Geretti et al., “Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients—impact of HIV subtypes and prior raltegravir experience,” Antiviral Research, vol. 90, no. 3, pp. 164–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  168. I. Malet, M. Wirden, S. Fourati et al., “Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 7, pp. 1481–1483, 2011. View at Publisher · View at Google Scholar · View at Scopus
  169. R. O’Neal, Dolutegravir: A New Integrase Inhibitor in Development, 2011.
  170. S. Min, E. De Jesus, L. McCurdy et al., “Early studies demonstrate potent activity and safety of experimental integrase inhibitor S/GSK1265744,” in Proceedings of the 49th Interscience Conference on Antimicrobials and Chemotherapy, San Francisco, Calif, USA, 2009.
  171. P. Cherepanov, “Integrase illuminated,” EMBO Reports, vol. 11, no. 5, article 328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. S. Hare, S. S. Gupta, E. Valkov, A. Engelman, and P. Cherepanov, “Retroviral intasome assembly and inhibition of DNA strand transfer,” Nature, vol. 464, no. 7286, pp. 232–236, 2010. View at Publisher · View at Google Scholar · View at Scopus
  173. L. Krishnan, X. Li, H. L. Naraharisetty, S. Hare, P. Cherepanov, and A. Engelman, “Structure-based modeling of the functional HIV-1 intasome and its inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 36, pp. 15910–15915, 2010. View at Publisher · View at Google Scholar · View at Scopus
  174. P. Cherepanov, G. N. Maertens, and S. Hare, “Structural insights into the retroviral DNA integration apparatus,” Current Opinion in Structural Biology, vol. 21, no. 2, pp. 249–256, 2011. View at Publisher · View at Google Scholar · View at Scopus
  175. L. H. Hall, “A structure-information approach to the prediction of biological activities and properties,” Chemistry & Biodiversity, vol. 1, no. 1, pp. 183–201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  176. Q. Liu, H. Zhou, L. Liu, X. Chen, R. Zhu, and Z. Cao, “Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study,” BMC Bioinformatics, vol. 12, article 294, 2011. View at Publisher · View at Google Scholar · View at Scopus
  177. C. Liao and M. C. Nicklaus, “Computer tools in the discovery of HIV-1 integrase inhibitors,” Future Medicinal Chemistry, vol. 2, no. 7, pp. 1123–1140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  178. M. S. Egbertson, J. S. Wai, M. Cameron et al., “Discovery of MK-0536: a potential second-generation HIV-1 integrase strand transfer inhibitor with a high genetic barrier to mutation,” in Antiviral Drugs: From Basic Discovery Through Clinical Trials, W. M. Kazmierski, Ed., John Wiley & Sons, Hoboken, NJ, USA, 2011. View at Google Scholar
  179. M. Métifiot, B. Johnson, S. Smith et al., “MK-0536 inhibits HIV-1 integrases resistant to raltegravir,” Antimicrob Agents Chemother, vol. 55, 11, pp. 5127–5133, 2011. View at Google Scholar
  180. I. LLC, Terephthalamate compounds and compositions, and their use as HIV integrase inhibitors, 2007.
  181. P. Pace, M. E. Di Francesco, C. Gardelli et al., “Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors,” Journal of Medicinal Chemistry, vol. 50, no. 9, pp. 2225–2239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  182. E. Muraglia, O. Kinzel, C. Gardelli et al., “Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors,” Journal of Medicinal Chemistry, vol. 51, no. 4, pp. 861–874, 2008. View at Publisher · View at Google Scholar · View at Scopus
  183. V. N. Telvekar and K. N. Patel, “Pharmacophore development and docking studies of the HIV-1 integrase inhibitors derived from N-methylpyrimidones, dihydroxypyrimidines, and bicyclic pyrimidinones,” Chemical Biology and Drug Design, vol. 78, no. 1, pp. 150–160, 2011. View at Publisher · View at Google Scholar
  184. T. W. Johnson, S. P. Tanis, S. L. Butler et al., “Design and synthesis of novel N-hydroxy-dihydronaphthyridinones as potent and orally bioavailable HIV-1 integrase inhibitors,” Journal of Medicinal Chemistry, vol. 54, no. 9, pp. 3393–3417, 2011. View at Publisher · View at Google Scholar · View at Scopus
  185. J. S. Wai, B. Kim, T. E. Fisher et al., “Dihydroxypyridopyrazine-1,6-dione HIV-1 integrase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 20, pp. 5595–5599, 2007. View at Publisher · View at Google Scholar
  186. A. P. Toropova, A. A. Toropov, E. Benfenati, and G. Gini, “Simplified molecular input-line entry system and International Chemical Identifier in the QSAR analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors,” Chemical Biology and Drug Design, vol. 77, no. 5, pp. 343–360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  187. J. Y. Nagasawa, J. Song, H. Chen et al., “6-Benzylamino 4-oxo-1,4-dihydro-1,8-naphthyridines and 4-oxo-1,4- dihydroquinolines as HIV integrase inhibitors,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 2, pp. 760–763, 2011. View at Publisher · View at Google Scholar · View at Scopus
  188. B. Van Maele, K. Busschots, L. Vandekerckhove, F. Christ, and Z. Debyser, “Cellular co-factors of HIV-1 integration,” Trends in Biochemical Sciences, vol. 31, no. 2, pp. 98–105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  189. R. D. Sloan and M. A. Wainberg, “The role of unintegrated DNA in HIV infection,” Retrovirology, vol. 8, article 52, 2011. View at Publisher · View at Google Scholar · View at Scopus
  190. A. Zamborlini, A. Coiffic, G. Beauclair et al., “Impairment of human immunodeficiency virus type-1 integrase SUMOylation correlates with an early replication defect,” The Journal of Biological Chemistry, vol. 286, no. 23, pp. 21013–21022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  191. M. Terreni, P. Valentini, V. Liverani et al., “GCN5-dependent acetylation of HIV-1 integrase enhances viral integration,” Retrovirology, vol. 7, article 18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  192. M. J. Buzon, K. Seiss, R. Weiss et al., “Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers,” Journal of Virology, vol. 85, no. 18, pp. 9646–9650, 2011. View at Publisher · View at Google Scholar
  193. F. Christ, A. Voet, A. Marchand et al., “Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication,” Nature Chemical Biology, vol. 6, no. 6, pp. 442–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  194. M. McNeely, J. Hendrix, K. Busschots et al., “In vitro DNA tethering of HIV-1 integrase by the transcriptional coactivator LEDGF/p75,” Journal of Molecular Biology, vol. 410, no. 5, pp. 811–830, 2011. View at Publisher · View at Google Scholar · View at Scopus
  195. L. De Luca, S. Ferro, R. Gitto et al., “Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor,” Bioorganic and Medicinal Chemistry, vol. 18, no. 21, pp. 7515–7521, 2010. View at Publisher · View at Google Scholar · View at Scopus
  196. P. Madlala, R. Gijsbers, F. Christ et al., “Association of polymorphisms in the LEDGF/p75 gene (PSIP1) with susceptibility to HIV-1 infection and disease progression,” AIDS, vol. 25, no. 14, pp. 1711–1719, 2011. View at Publisher · View at Google Scholar
  197. A. M. Meehan, D. T. Saenz, J. Morrison, C. Hu, M. Peretz, and E. M. Poeschla, “LEDGF dominant interference proteins demonstrate prenuclear exposure of HIV-1 integrase and synergize with LEDGF depletion to destroy viral infectivity,” Journal of Virology, vol. 85, no. 7, pp. 3570–3583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  198. L. de Luca, S. Ferro, F. Morreale, and A. Chimirri, “Inhibition of the interaction between HIV-1 integrase and its cofactor LEDGF/P75: a promising approach in anti-retroviral therapy,” Mini-Reviews in Medicinal Chemistry, vol. 11, no. 8, pp. 714–727, 2011. View at Google Scholar · View at Scopus
  199. L. DeLuca, S. Ferro, F. Morreale, S. DeGrazia, and A. Chimirri, “Inhibitors of the Interactions between HIV-1 IN and the Cofactor LEDGF/p75,” ChemMedChem, vol. 6, no. 7, pp. 1184–1191, 2011. View at Publisher · View at Google Scholar · View at Scopus
  200. C. Fenwick, R. B. M. Cordingley, P. Edwards et al., “BI 224436, a Non-Catalytic Site Integrase Inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1,” in Proceedings of the 51st Interscience Conference on Antimicrobials and Chemotherapy, Chicago, Ill, USA, 2011.
  201. S. Aslanyan, C. B. J. P. Sabo, J. Habeck et al., “Safety and pharmacokinetics (PK) of single rising oral doses of a novel HIV integrase inhibitor in healthy volunteers,” in Proceedings of the 51st Interscience Conference on Antimicrobials and Chemotherapy, Chicago, Ill, USA, 2011.
  202. J. Tang, K. Maddali, C. D. Dreis et al., “N-3 hydroxylation of pyrimidine-2,4-diones yields dual inhibitors of HIV reverse transcriptase and integrase,” ACS Medicinal Chemistry Letters, vol. 2, no. 1, pp. 63–67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  203. Z. Wang, J. Tang, C. E. Salomon, C. D. Dreis, and R. Vince, “Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase,” Bioorganic and Medicinal Chemistry, vol. 18, no. 12, pp. 4202–4211, 2010. View at Publisher · View at Google Scholar · View at Scopus
  204. R. D. Santo, “Diketo acids derivatives as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain,” Current Medicinal Chemistry, vol. 18, no. 22, pp. 3335–3342, 2011. View at Publisher · View at Google Scholar · View at Scopus
  205. B. G. Brenner, M. Lowe, D. Moisi et al., “Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors,” Journal of Medical Virology, vol. 83, no. 5, pp. 751–759, 2011. View at Publisher · View at Google Scholar · View at Scopus
  206. E. Z. Loizidou, I. Kousiappa, C. D. Zeinalipour-Yazdi, D. A. M. C. Van De Vijver, and L. G. Kostrikis, “Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses,” Biochemistry, vol. 48, no. 1, pp. 4–6, 2009. View at Publisher · View at Google Scholar · View at Scopus
  207. I. Malet, S. Fourati, C. Charpentier et al., “The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype,” Journal of Antimicrobial Chemotherapy, vol. 66, no. 12, pp. 2827–2830, 2011. View at Publisher · View at Google Scholar
  208. J. B. Whitney, S.-Y. Lim, and M. A. Wainberg, “Evolutionary mechanisms of retroviral persistence,” AIDS Reviews, vol. 13, no. 4, pp. 234–239, 2011. View at Google Scholar
  209. M. A. Wainberg, G. J. Zaharatos, and B. G. Brenner, “Development of antiretroviral drug resistance,” The New England Journal of Medicine, vol. 365, no. 7, pp. 637–646, 2011. View at Google Scholar
  210. O. Delelis, K. Carayon, A. Saïb, E. Deprez, and J. F. Mouscadet, “Integrase and integration: biochemical activities of HIV-1 integrase,” Retrovirology, vol. 5, article 114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  211. X. Li, L. Krishnan, P. Cherepanov, and A. Engelman, “Structural biology of retroviral DNA integration,” Virology, vol. 411, no. 2, pp. 194–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  212. D. J. Hazuda, P. Felock, M. Witmer et al., “Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells,” Science, vol. 287, no. 5453, pp. 646–650, 2000. View at Publisher · View at Google Scholar · View at Scopus
  213. A. Engelman and P. Cherepanov, “The structural biology of HIV-1: mechanistic and therapeutic insights,” Nature Reviews Microbiology, vol. 10, no. 4, pp. 279–290, 2012. View at Publisher · View at Google Scholar
  214. J. J. Schafer and K. E. Squires, “Integrase inhibitors: a novel class of antiretroviral agents,” Annals of Pharmacotherapy, vol. 44, no. 1, pp. 145–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  215. D. A. Cooper, R. T. Steigbigel, J. M. Gatell et al., “Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection,” The New England Journal of Medicine, vol. 359, no. 4, pp. 355–365, 2008. View at Publisher · View at Google Scholar
  216. B. Y. T. Nguyen, R. D. Isaacs, H. Teppler et al., “Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium,” Annals of the New York Academy of Sciences, vol. 1222, no. 1, pp. 83–89, 2011. View at Publisher · View at Google Scholar · View at Scopus
  217. R. T. Steigbigel, D. A. Cooper, P. N. Kumar et al., “Raltegravir with optimized background therapy for resistant HIV-1 infection,” The New England Journal of Medicine, vol. 359, no. 4, pp. 339–354, 2008. View at Publisher · View at Google Scholar
  218. T. Wills and V. Vega, “Elvitegravir: a once-daily inhibitor of HIV-1 integrase,” Expert Opinion on Investigational Drugs, vol. 21, no. 3, pp. 395–401, 2012. View at Publisher · View at Google Scholar
  219. C. Katlama and R. Murphy, “Dolutegravir for the treatment of HIV,” Expert Opinion on Investigational Drugs, vol. 21, no. 4, pp. 523–530, 2012. View at Publisher · View at Google Scholar
  220. M. Kobayashi, K. Nakahara, T. Seki et al., “Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants,” Antiviral Research, vol. 80, no. 2, pp. 213–222, 2008. View at Publisher · View at Google Scholar · View at Scopus
  221. K. Nakahara, C. Wakasa-Morimoto, M. Kobayashi et al., “Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics,” Antiviral Research, vol. 81, no. 2, pp. 141–146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  222. R. T. Steigbigel, D. A. Cooper, H. Teppler et al., “Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatmentexperienced patients with drugresistant hiv infection: week 96 results of the benchmrk 1 and 2 phase III trials,” Clinical Infectious Diseases, vol. 50, no. 4, pp. 605–612, 2010. View at Publisher · View at Google Scholar · View at Scopus
  223. O. Goethals, M. Van Ginderen, A. Vos et al., “Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor,” Antiviral Research, vol. 91, no. 2, pp. 167–176, 2011. View at Publisher · View at Google Scholar · View at Scopus
  224. T. Bar-Magen, R. D. Sloan, V. H. Faltenbacher et al., “Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes,” Retrovirology, vol. 6, article 103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  225. T. Bar-Magen, R. D. Sloan, D. A. Donahue et al., “Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor,” Journal of Virology, vol. 84, no. 18, pp. 9210–9216, 2010. View at Publisher · View at Google Scholar · View at Scopus
  226. L. Van Wesenbeeck, E. Rondelez, M. Feyaerts et al., “Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 1, pp. 321–325, 2011. View at Publisher · View at Google Scholar · View at Scopus
  227. I. Song, J. Borland, S. Min et al., “Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 7, pp. 3517–3521, 2011. View at Publisher · View at Google Scholar · View at Scopus
  228. S. Min, I. Song, J. Borland et al., “Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 1, pp. 254–258, 2010. View at Publisher · View at Google Scholar · View at Scopus
  229. S. Min, L. Sloan, E. DeJesus et al., “Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults,” AIDS, vol. 25, no. 14, pp. 1737–1745, 2011. View at Publisher · View at Google Scholar · View at Scopus
  230. M. Kobayashi, T. Yoshinaga, T. Seki et al., “In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 2, pp. 813–821, 2011. View at Publisher · View at Google Scholar · View at Scopus
  231. O. Goethals, A. Vos, M. Van Ginderen et al., “Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles,” Virology, vol. 402, no. 2, pp. 338–346, 2010. View at Publisher · View at Google Scholar · View at Scopus
  232. S. Hare, S. J. Smith, M. Métifiot et al., “Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572),” Molecular Pharmacology, vol. 80, no. 4, pp. 565–572, 2011. View at Publisher · View at Google Scholar
  233. T. Seki et al., “S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones,” in Proceedings of the 17th Conference on retroviruses and opportunistic infections (CROI '10), San Francisco, Calif, USA, 2010.
  234. P. K. Quashie, T. Mesplède, Y.-S. Han et al., “Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir,” Journal of Virology, vol. 86, no. 5, pp. 2696–2705, 2012. View at Publisher · View at Google Scholar
  235. L. Krishnan, X. Li, H. L. Naraharisetty, S. Hare, P. Cherepanov, and A. Engelman, “Structure-based modeling of the functional HIV-1 intasome and its inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 36, pp. 15910–15915, 2010. View at Publisher · View at Google Scholar · View at Scopus
  236. S. Hare, S. S. Gupta, E. Valkov, A. Engelman, and P. Cherepanov, “Retroviral intasome assembly and inhibition of DNA strand transfer,” Nature, vol. 464, no. 7286, pp. 232–236, 2010. View at Publisher · View at Google Scholar · View at Scopus
  237. P. Cherepanov, G. N. Maertens, and S. Hare, “Structural insights into the retroviral DNA integration apparatus,” Current Opinion in Structural Biology, vol. 21, no. 2, pp. 249–256, 2011. View at Publisher · View at Google Scholar · View at Scopus
  238. G. N. Maertens, S. Hare, and P. Cherepanov, “The mechanism of retroviral integration from X-ray structures of its key intermediates,” Nature, vol. 468, no. 7321, pp. 326–329, 2010. View at Publisher · View at Google Scholar · View at Scopus
  239. A. S. Espeseth, P. Felock, A. Wolfe et al., “HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 21, pp. 11244–11249, 2000. View at Google Scholar · View at Scopus
  240. S. Hare, A. M. Vos, R. F. Clayton, J. W. Thuring, M. D. Cummings, and P. Cherepanov, “Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 46, pp. 20057–20062, 2010. View at Publisher · View at Google Scholar · View at Scopus
  241. J. A. Grobler, K. Stillmock, B. Hu et al., “Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 10, pp. 6661–6666, 2002. View at Publisher · View at Google Scholar · View at Scopus
  242. A. Bacchi, M. Carcelli, C. Compari et al., “Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors,” Journal of Medicinal Chemistry, vol. 54, no. 24, pp. 8407–8420, 2011. View at Publisher · View at Google Scholar
  243. A. Bacchi, M. Carcelli, C. Compari et al., “HIV-1 in strand transfer chelating inhibitors: a focus on metal binding,” Molecular Pharmaceutics, vol. 8, no. 2, pp. 507–519, 2011. View at Publisher · View at Google Scholar · View at Scopus
  244. A. A. Johnson, W. Santos, G. C. G. Pais et al., “Integration requires a specific interaction of the donor DNA terminal 5′-cytosine with glutamine 148 of the HIV-1 integrase flexible loop,” The Journal of Biological Chemistry, vol. 281, no. 1, pp. 461–467, 2006. View at Publisher · View at Google Scholar · View at Scopus
  245. K. D. Jayappa, Z. Ao, M. Yang, J. Wang, and X. Yao, “Identification of critical motifs within HIV-1 integrase required for importin α3 interaction and viral cDNA nuclear import,” Journal of Molecular Biology, vol. 410, no. 5, pp. 847–862, 2011. View at Publisher · View at Google Scholar · View at Scopus
  246. M. Métifiot, N. Vandegraaff, K. Maddali et al., “Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143,” AIDS, vol. 25, no. 9, pp. 1175–1178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  247. O. Goethals, R. Clayton, M. Van Ginderen et al., “Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors,” Journal of Virology, vol. 82, no. 21, pp. 10366–10374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  248. J. L. Blanco, V. Varghese, S. Y. Rhee, J. M. Gatell, and R. W. Shafer, “HIV-1 integrase inhibitor resistance and its clinical implications,” Journal of Infectious Diseases, vol. 203, no. 9, pp. 1204–1214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  249. I. B. Dicker, B. Terry, Z. Lin et al., “Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors,” The Journal of Biological Chemistry, vol. 283, no. 35, pp. 23599–23609, 2008. View at Publisher · View at Google Scholar · View at Scopus
  250. D. J. Hazuda, “Resistance to inhibitors of the human immunodeficiency virus type 1 integration,” Brazilian Journal of Infectious Diseases, vol. 14, no. 5, pp. 513–518, 2010. View at Publisher · View at Google Scholar · View at Scopus
  251. R. W. Shafer, “Rationale and uses of a public HIV drug-resistance database,” Journal of Infectious Diseases, vol. 194, supplement 1, pp. S51–S58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  252. M. Kawonga, K. Blanchard, D. Cooper et al., “Integrating medical abortion into safe abortion services: experience from three pilot sites in South Africa,” Journal of Family Planning and Reproductive Health Care, vol. 34, no. 3, pp. 159–164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  253. K. E. Hightower, R. Wang, F. DeAnda et al., “Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 10, pp. 4552–4559, 2011. View at Publisher · View at Google Scholar
  254. R. A. Copeland, D. L. Pompliano, and T. D. Meek, “Drug-target residence time and its implications for lead optimization,” Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 730–739, 2006. View at Publisher · View at Google Scholar · View at Scopus
  255. V. R. de Soultrait, C. Desjobert, and L. Tarrago-Litvak, “Peptides as new inhibitors of HIV-1 reverse transcriptase and integrase,” Current Medicinal Chemistry, vol. 10, no. 18, pp. 1765–1778, 2003. View at Publisher · View at Google Scholar · View at Scopus
  256. M. Oliveira, B. G. Brenner, and M. A. Wainberg, “Isolation of drug-resistant mutant HIV variants using tissue culture drug selection,” Methods in Molecular Biology, vol. 485, pp. 427–433, 2009. View at Publisher · View at Google Scholar · View at Scopus
  257. G. Jones, F. Yu, X. Chen et al., “In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303),” in Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections (CROI '07), Los Angeles, California, 2007.
  258. K. Shimura, E. Kodama, Y. Sakagami et al., “Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137),” Journal of Virology, vol. 82, no. 2, pp. 764–774, 2008. View at Publisher · View at Google Scholar · View at Scopus
  259. F. M. Codoñer, C. Pou, A. Thielen et al., “Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure,” Antiviral Research, vol. 88, no. 3, pp. 281–286, 2010. View at Publisher · View at Google Scholar · View at Scopus
  260. D. Armenia, I. Vandenbroucke, L. Fabeni et al., “Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing,” Journal of Infectious Diseases, vol. 205, no. 4, pp. 557–567, 2012. View at Publisher · View at Google Scholar
  261. B. Winters, R. Lloyd Jr., M. Miller et al., “Evolution of IN inhibitor resistance mutations in patients failling elvitegravir-containing regimens,” in Proceedings of the 19th Conference on retroviruses and opportunistic infections (CROI '12), Seattle, Wash, USA, 2012, Abstract no. 701.
  262. F. Canducci, M. Sampaolo, M. C. Marinozzi et al., “Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies,” AIDS, vol. 23, no. 4, pp. 455–460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  263. C. Charpentier, M. Karmochkine, D. Laureillard et al., “Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy,” HIV Medicine, vol. 9, no. 9, pp. 765–770, 2008. View at Publisher · View at Google Scholar · View at Scopus
  264. S. Fransen, M. Karmochkine, W. Huang, L. Weiss, C. J. Petropoulos, and C. Charpentier, “Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, pp. 4522–4524, 2009. View at Publisher · View at Google Scholar · View at Scopus
  265. I. Malet, O. Delelis, C. Soulie et al., “Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients,” Journal of Antimicrobial Chemotherapy, vol. 63, no. 4, pp. 795–804, 2009. View at Publisher · View at Google Scholar · View at Scopus
  266. J. F. Mouscadet, O. Delelis, A. G. Marcelin, and L. Tchertanov, “Resistance to HIV-1 integrase inhibitors: a structural perspective,” Drug Resistance Updates, vol. 13, no. 4-5, pp. 139–150, 2010. View at Publisher · View at Google Scholar · View at Scopus
  267. A. Sato et al., “In vitro passage of drug resistant HIV-1 against a next generation integrase inhibitor (INI), S/GSK1349572,” in Proceedings of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC '09), San Francisco, Calif, USA, 2009.
  268. N. A. Margot, R. M. Hluhanich, G. S. Jones et al., “In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4,” Antiviral Research, vol. 93, no. 2, pp. 288–296, 2012. View at Publisher · View at Google Scholar
  269. F. Canducci, E. R. Ceresola, E. Boeri et al., “Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir,” Journal of Infectious Diseases, vol. 204, no. 11, pp. 1811–1815, 2011. View at Publisher · View at Google Scholar
  270. H. J. Stellbrink et al., “Dolutegravir in combination therapy exhibits rapid and sustained antiviral response in ARV-naïve adults: 96-week results from SPRING-1 (ING112276),” in Proceedings of the 19th Conference on Retroviruses and Opportunistic Infections (CROI '12), Seattle, Wash, USA, 2012, Abstract no. 102LB.
  271. J. Van Lunzen, F. Maggiolo, J. R. Arribas et al., “Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial,” The Lancet Infectious Diseases, vol. 12, no. 2, pp. 111–118, 2012. View at Publisher · View at Google Scholar
  272. J. Enron, P. Kumar, A. Lazzarin et al., “DTG in subjects with HIV exhibiting RAL resistance: functional monotherapy results of VIKING study cohort II,” in Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections (CROI '11), Boston, Mass, USA, 2011, Abstract no. 151LB.
  273. M. Kobayashi, T. Seki, T. Yoshinaga et al., “Antiviral activity in vitro of the INI, dolutegravir, against raltegravir-resistant HIV-2 mutants,” in Proceedings of the 19th Conference on retroviruses and opportunistic infections (CROI '12), Seattle, Wash, USA, 2012, Abstract no. 691.